Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Viral Hepat ; 24 Suppl 2: 8-24, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-29105285

RESUMO

Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.


Assuntos
Gerenciamento Clínico , Saúde Global , Hepatite C Crônica/epidemiologia , Antivirais/uso terapêutico , Política de Saúde , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/mortalidade , Hepatite C Crônica/terapia , Humanos , Transplante de Fígado , Prevalência
2.
J Viral Hepat ; 24 Suppl 2: 44-63, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-29105286

RESUMO

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.


Assuntos
Gerenciamento Clínico , Saúde Global , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/mortalidade , Viremia/epidemiologia , Viremia/mortalidade , Antivirais/uso terapêutico , Política de Saúde , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Humanos , Incidência , Prevalência , Viremia/diagnóstico , Viremia/tratamento farmacológico
3.
J Viral Hepat ; 24 Suppl 2: 25-43, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-29105283

RESUMO

Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV-related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high-treatment rate will contribute to a reduction in total cases and HCV-related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV-related morbidity and mortality.


Assuntos
Saúde Global , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/mortalidade , Modelos Estatísticos , Viremia/epidemiologia , Viremia/mortalidade , Antivirais/uso terapêutico , Política de Saúde , Hepatite C Crônica/tratamento farmacológico , Humanos , Incidência , Prevalência , Viremia/tratamento farmacológico
4.
J Viral Hepat ; 18(7): e258-62, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21108700

RESUMO

Among individuals with chronic hepatitis C virus (HCV) infection, approximately 30% of patients show persistently normal alanine aminotransferase (PNALT). Individuals with PNALT have been historically excluded from antiviral treatment. However, some studies have reported sudden worsening of disease in patients with PNALT, suggesting the need to treat such individuals. To evaluate this further, we compared fibrosis severity and response to treatment in patients with PNALT to patients with abnormal ALT. In addition, we investigated whether liver histology and schistosomiasis affect response to treatment differently in those with PNALT and abnormal ALT. A retrospective cohort study of 176 HCV-Genotype 4 (HCV-G4) patients treated with pegylated interferon (PEG-IFN) and ribavirin. Of 176 cases studied, 53 (30.1%) had normal ALT. Prevalence of pretreatment severe fibrosis, sustained virological response (SVR) and relapse were not significantly different in patients with PNALT (26%, 66% and 5.7% respectively) compared to those with abnormal ALT (32.5%, 60.7%, and 6.6% respectively). Multivariable logistic regression revealed that pretreatment ALT, pretreatment viral load, inflammation and schistosomiasis were not significantly associated with SVR [OR (95% CI), 0.75 (0.34-1.65); 0.92 (0.61-1.37); 1.64 (0.64-4.18); 0.90 (0.44-1.84) respectively]. Severe fibrosis was the only significant predictor of SVR [OR (95% CI), 0.38 (0.14-0.99)]. PNALT does not reflect the degree of fibrotic changes or predict SVR. Furthermore, schistosomiasis is a predictor of neither fibrosis nor poor response in patients with PNALT. Severe fibrosis is a strong and independent predictor of response to treatment. Therefore, it is important to treat individuals with PNALT levels regardless of schistosomiasis.


Assuntos
Alanina Transaminase/sangue , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepatite C Crônica/tratamento farmacológico , Esquistossomose/complicações , Transaminases/metabolismo , Adulto , Antivirais/uso terapêutico , Estudos de Coortes , Feminino , Genótipo , Hepatite C Crônica/complicações , Hepatite C Crônica/virologia , Humanos , Interferon-alfa/uso terapêutico , Cirrose Hepática/tratamento farmacológico , Cirrose Hepática/etiologia , Cirrose Hepática/fisiopatologia , Cirrose Hepática/virologia , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Polietilenoglicóis/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Ribavirina/uso terapêutico , Resultado do Tratamento
5.
Saudi Med J ; 20(8): 582-6, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27645174

RESUMO

Full text is available as a scanned copy of the original print version.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA